MK-677

Dylan Gemelli notes that when he began researching peptides and SARMs in 2011, he found studies dating back to the 1990s for MK-2866 (Ostarine) and MK-677 (Ibutamoren). While MK-2866 and MK-677 are technically SARMs/secretagogues rather than classical peptides, they were discussed in the same context as peptides in the early underground research community. No specific study details or dosages are referenced from these older studies.

Ben Greenfield warns that ipamorelin, sermorelin, and MK-677 all target the same growth hormone receptors and stacking them creates exponentially compounded side effects without proportional benefit. He uses this as an example of how biohackers create dangerous redundancy by combining compounds with overlapping mechanisms of action. No specific dosages are mentioned, but the warning applies to any combination of these GH-axis compounds.

In the context of discussing peptides for muscular dystrophy and mitochondrial dysfunction, Dr. Yurth specifically refers to ibutamoren (epimorelin/MK-677) as 'another mitochondrial peptide,' suggesting it has relevance beyond just GH secretion. This is a brief but distinct categorization. No dosage is specified.

Dr. Yurth lists growth hormone secretagogues — CJC, ipamorelin, tesamorelin, and ibutamoren (epimorelin) — as high-value adjuncts in a muscle-building protocol for patients with muscular dystrophy or sarcopenia. These are described as supporting the broader mitochondrial and anabolic environment needed for muscle growth. No specific dosages are provided for these agents in this context.

MK-677 is a non-selective GHS-R1A agonist that causes elevated cortisol (muscle wasting, metabolic problems) and elevated prolactin (gynecomastia, sexual dysfunction, lactation). Dr. Bachmeyer positions Ipamorelin as the superior choice due to its selectivity, producing GH release without collateral hormonal disruption.